表紙:遺伝子治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)
市場調査レポート
商品コード
1058443

遺伝子治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)

Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 145 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
遺伝子治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2022年~2027年)
出版日: 2022年02月12日
発行: IMARC Services Private Limited
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝子治療の市場規模は、2021年に37億7,000万米ドルに達しました。今後、2022年~2027年の間に15.60%のCAGRで拡大し、2027年までに95億米ドルになると予測されています。

遺伝性疾患や後天性疾患の増加、医療施設へのアクセスの容易さなどが、患者の生活の質を向上させるための遺伝子治療の需要を促進する重要な要因の1つとなっています。さらに、筋ジストロフィーや嚢胞性線維症などの遺伝性疾患が子供や若年層で増加していることが、市場の成長を後押ししています。

当レポートでは、世界の遺伝子治療市場について調査し、市場の概要とともに、遺伝子タイプ別、ベクタータイプ別、投与方法別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の遺伝子治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場の内訳、遺伝子タイプ別

  • 抗原
  • サイトカイン
  • 腫瘍抑制因子
  • 自殺遺伝子
  • 欠乏
  • 成長因子
  • 受容体
  • その他

第7章 市場の内訳、ベクタータイプ別

  • ウイルスベクター
    • 主要セグメント
  • 非ウイルス技術
    • 主要セグメント

第8章 市場の内訳、投与方法別

  • In-Vivo 遺伝子治療
  • Ex-Vivo 遺伝子治療

第9章 市場の内訳、用途別

  • 腫瘍学的障害
  • 希少疾患
  • 心血管疾患
  • 神経学的障害
  • 感染症
  • その他

第10章 市場の内訳、地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場の内訳

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics plc
    • Adverum Biotechnologies Inc.
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.
    • Bluebird Bio Inc.
    • Mustang Bio Inc.(Fortress Biotech Inc.)
    • Novartis AG
    • Orchard Therapeutics plc
    • UniQure N.V.
    • Voyager Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Gene Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Gene Therapy Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Gene Therapy Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Gene Therapy Market: Breakup by Gene Type (in %), 2021
  • Figure 5: Global: Gene Therapy Market: Breakup by Vector Type (in %), 2021
  • Figure 6: Global: Gene Therapy Market: Breakup by Delivery Method (in %), 2021
  • Figure 7: Global: Gene Therapy Market: Breakup by Application (in %), 2021
  • Figure 8: Global: Gene Therapy Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Gene Therapy (Antigen) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Gene Therapy (Antigen) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Gene Therapy (Cytokine) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Gene Therapy (Cytokine) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Gene Therapy (Tumor Suppressor) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Gene Therapy (Tumor Suppressor) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Gene Therapy (Suicide Gene) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Gene Therapy (Suicide Gene) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Gene Therapy (Deficiency) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Gene Therapy (Deficiency) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Gene Therapy (Growth Factors) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Gene Therapy (Growth Factors) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Gene Therapy (Receptors) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Gene Therapy (Receptors) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Gene Therapy (Other Gene Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Gene Therapy (Other Gene Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Gene Therapy (Viral Vector) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Gene Therapy (Viral Vector) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Gene Therapy (Non-Viral Techniques) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Gene Therapy (Non-Viral Techniques) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Gene Therapy (In-Vivo Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Gene Therapy (In-Vivo Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Gene Therapy (Ex-Vivo Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Gene Therapy (Oncological Disorders) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Gene Therapy (Oncological Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Gene Therapy (Rare Diseases) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Gene Therapy (Rare Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Gene Therapy (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Gene Therapy (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: Global: Gene Therapy (Neurological Disorders) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: Global: Gene Therapy (Neurological Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: Global: Gene Therapy (Infectious Disease) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: Global: Gene Therapy (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Global: Gene Therapy (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Global: Gene Therapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: North America: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: North America: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: United States: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: United States: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: Canada: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: Canada: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Asia-Pacific: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Asia-Pacific: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: China: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: China: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: Japan: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: Japan: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: India: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: India: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: South Korea: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: South Korea: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: Australia: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: Australia: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Indonesia: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Indonesia: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: Others: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: Others: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: Europe: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: Europe: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Germany: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Germany: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: France: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: France: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: United Kingdom: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: United Kingdom: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Italy: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Italy: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Spain: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Spain: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Russia: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Russia: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Others: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Others: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Latin America: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Latin America: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Brazil: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Brazil: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 87: Mexico: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 88: Mexico: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 89: Others: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 90: Others: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 91: Middle East and Africa: Gene Therapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 92: Middle East and Africa: Gene Therapy Market: Breakup by Country (in %), 2021
  • Figure 93: Middle East and Africa: Gene Therapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 94: Global: Gene Therapy Industry: SWOT Analysis
  • Figure 95: Global: Gene Therapy Industry: Value Chain Analysis
  • Figure 96: Global: Gene Therapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gene Therapy Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Gene Therapy Market Forecast: Breakup by Gene Type (in Million US$), 2022-2027
  • Table 3: Global: Gene Therapy Market Forecast: Breakup by Vector Type (in Million US$), 2022-2027
  • Table 4: Global: Gene Therapy Market Forecast: Breakup by Delivery Method (in Million US$), 2022-2027
  • Table 5: Global: Gene Therapy Market Forecast: Breakup by Application (in Million US$), 2022-2027
  • Table 6: Global: Gene Therapy Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Gene Therapy Market: Competitive Structure
  • Table 8: Global: Gene Therapy Market: Key Players
目次
Product Code: SR0222A294_Report

The global gene therapy market reached a value of US$ 3.77 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.5 Billion by 2027 exhibiting a CAGR of 15.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Gene therapy is a technique for preventing disease progression by modifying the expression of mutated genes or altering the biological properties of living cells for therapeutic use. It improves the ability of the body to fight against a wide range of diseases, such as cancer, diabetes, hemophilia, cystic fibrosis, heart disease, and acquired immunodeficiency syndrome (AIDS). Nowadays, a wide variety of gene therapy products are available worldwide, which include viral vectors, bacterial vectors, plasmid deoxyribonucleic acid (DNA), human gene-editing technology, and patient-derived cellular gene therapy.

Gene Therapy Market Trends:

  • The growing prevalence of inherited diseases and acquired disorders, in confluence with easy access to healthcare facilities, represents one of the key factors catalyzing the demand for gene therapy to improve the quality of life of patients. Moreover, the rising cases of genetic disorders, such as muscular dystrophy and cystic fibrosis, in children and young adults are bolstering the market growth. In line with this, the increasing geriatric population, which is more susceptible to develop infectious diseases on account of inappropriate gene activity, is contributing to the market growth. Apart from this, the development of new gene therapy that offers a safer, non-addictive alternative to opioids in treating a broad range of chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, is favoring the market growth. In addition, a large variety of therapeutic genes are under investigation, including tumor suppressor, anti-angiogenesis, inflammatory cytokine, and micro ribonucleic acid (RNA) genes. These genes can assist in treating cancer, leukemia, severe combined immune deficiency, and blindness caused by retinitis pigmentosa, which is anticipated to stimulate the growth of the market.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global gene therapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on gene type, vector type, delivery method and application.

Breakup by Gene Type:

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide Gene
  • Deficiency
  • Growth Factors
  • Receptors
  • Others

Breakup by Vector Type:

  • Viral Vector
  • Adenoviruses
  • Lentiviruses
  • Retroviruses
  • Adeno-Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
  • Non-Viral Techniques
  • Naked and Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

Breakup by Delivery Method:

  • In-Vivo Gene Therapy
  • Ex-Vivo Gene Therapy

Breakup by Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Disease
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc. Key Questions Answered in This Report:

  • How has the global gene therapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global gene therapy market?
  • What are the key regional markets?
  • What is the breakup of the market based on the gene type?
  • What is the breakup of the market based on the vector type?
  • What is the breakup of the market based on the delivery method?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global gene therapy market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gene Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Gene Type

  • 6.1 Antigen
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cytokine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Tumor Suppressor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Suicide Gene
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Deficiency
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Growth Factors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Receptors
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Vector Type

  • 7.1 Viral Vector
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Adenoviruses
      • 7.1.2.2 Lentiviruses
      • 7.1.2.3 Retroviruses
      • 7.1.2.4 Adeno-Associated Virus
      • 7.1.2.5 Herpes Simplex Virus
      • 7.1.2.6 Poxvirus
      • 7.1.2.7 Vaccinia Virus
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Non-Viral Techniques
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Naked and Plasmid Vectors
      • 7.2.2.2 Gene Gun
      • 7.2.2.3 Electroporation
      • 7.2.2.4 Lipofection
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Delivery Method

  • 8.1 In-Vivo Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ex-Vivo Gene Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Oncological Disorders
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rare Diseases
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Cardiovascular Diseases
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Neurological Disorders
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Infectious Disease
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Others
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abeona Therapeutics Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Adaptimmune Therapeutics plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Adverum Biotechnologies Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Amgen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Astellas Pharma Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Biogen Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Bluebird Bio Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Mustang Bio Inc. (Fortress Biotech Inc.)
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Orchard Therapeutics plc
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 UniQure N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
    • 15.3.12 Voyager Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials